SNY Stock Price and Chart — NASDAQ:SNY

Overview

Financials News Ideas Discussions Technicals Forecast Seasonals Options Bonds

Key facts today

On May 30, 2025, Sanofi reported mixed Phase 3 results for itepekimab in COPD. The AERIFY-1 trial met its primary goal, while AERIFY-2 did not. Shares dropped 5.69% to $49.37.

Sanofi's Sarclisa received a positive recommendation from the European Medicines Agency for treating newly diagnosed multiple myeloma, pending final approval based on phase 3 trial results.

Analyze the impact Analyze the impact

About SANOFI

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Check out other big names from the same industry as SNY.